Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > June 23, 2020
Daily News
June 23, 2020
- Ayumi Chief Says Contender Debut Will Add Vigor to Enbrel Biosimilar Space, Sees Govt Fee Incentive as Booster
June 23, 2020
- MHLW to Hasten Electronic Scrip Rollout to Summer 2022: Health Minister
June 23, 2020
- Takeda to Book One-Time Profit Gains after SHP647 Divestment Obligation Cleared
June 23, 2020
- Celgene’s CAR-T Therapy Filed in Japan for B-Cell Lymphoma: BMS
June 23, 2020
- Japan Likely to OK CureApp’s Smoking Cessation App in July
June 23, 2020
- Shionogi Licenses Rapid COVID-19 Diagnostic Methods Developed by 3 Universities
June 23, 2020
- Latuda Challenged Again over Use Patent Validity in US: Sumitomo Dainippon
June 23, 2020
- Sawai Snaps Up Rights for ALS Drug Candidate from Tokai Univ. Spin-Off, Its 1st Orphan Development
June 23, 2020
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…